Table 2. Inhibitory Activities of 7a against DNA Gyrase and Topo IV from S aureus, E. coli, A. baumannii, and P. aeruginosa.
| |
IC50 [nM]a |
|||
|---|---|---|---|---|
| enzyme | 7a | ciprofloxacin | novobiocin | |
| S. aureus | DNA gyraseb | 1.22 ± 0.04 | 12 170 ± 1 245 | 0.65 ± 0.03 |
| topo IVb | 8.0 ± 1.2 | 6 075 ± 1 648 | 13 265 ± 7 | |
| E. coli | DNA gyrasec | <10 | 120 ± 20 | 170 ± 20 |
| topo IVc | 44 ± 11 | 5 400 ± 2 100 | 11 000 ± 2 000 | |
| A. baumannii | DNA gyraseb | 2.42 ± 0.28 | 1 267 ± 344 | 2.17 ± 0.16 |
| topo IVb | 119.7 ± 8.34 | 2 885 ± 332 | 9 465 ± 799 | |
| P. aeruginosa | DNA gyrasec | <10 | ntd | nt |
| topo IVb | 27.5 ± 16.3 | 3 895 ± 63.6 | 8 365 ± 445 | |
IC50, concentration (mean ± SD of three independent experiments) that inhibits enzyme activity by 50%.
Tested in gel-based supercoiling (for DNA gyrase) and decatenation (for topo IV) assays.
Tested in supercoiling (for DNA gyrase) and relaxation (for topo IV) HTS assays.
nt, not tested.